GlassScriptPhysician profile
Jason Palermo
NPI 1053561977
$8,668.67
in general payments reported to CMS, 2019-2025
38 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $643 · 2021: $1,461 · 2022: $693 · 2023: $1,065 · 2024: $1,633 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,059 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,058.55 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,259.46 | 2019-2025 | Aveir, Perclose Prostyle, Navitor |
| Novartis Pharmaceuticals Corporation | $1,056.90 | 2019-2025 | |
| Boston Scientific Corporation | $939.89 | 2019-2024 | Watchman Flx |
| Pfizer INC. | $716.27 | 2019-2025 | |
| Amgen INC. | $640.62 | 2019-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $606.37 | 2021-2025 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $595.45 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $461.25 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $402.83 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $296.76 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $238.05 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.45 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $157.00 | 2019-2025 | Farxiga, Wainua |
| Regeneron Healthcare Solutions, INC. | $113.58 | 2019-2023 | Evkeeza |
| W. L. Gore & Associates, INC. | $104.44 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $103.18 | 2019-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $100.53 | 2021-2025 | |
| Cvrx, INC. | $98.63 | 2023-2024 | Barostim Neo System |
| Esperion Therapeutics, INC. | $95.55 | 2020-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $76.75 | 2019-2023 | |
| Scpharmaceuticals INC. | $60.72 | 2025 | |
| Inspire Medical Systems, INC. | $54.14 | 2024-2025 | Inspire |
| Daiichi Sankyo INC. | $32.51 | 2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $31.71 | 2025 | Opsumit, Uptravi |
| Kestra Medical Technology Services, INC. | $30.07 | 2023-2024 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $28.95 | 2022-2023 | Arcalyst |
| Glaxosmithkline, LLC. | $23.00 | 2025 | Shingrix, Arexvy |
| Lexicon Pharmaceuticals, INC. | $21.75 | 2023 | Inpefa |
| Elutia, INC. | $19.96 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $16.80 | 2019 | |
| Lilly USA, LLC | $16.76 | 2025 | Mounjaro, Zepbound |
| Alnylam Pharmaceuticals INC. | $16.31 | 2024 | Amvuttra |
| Edwards Lifesciences Corporation | $15.52 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kiniksa Pharmaceuticals International, Plc | $14.69 | 2024 | Arcalyst |
| Medicomp INC | $13.32 | 2024 | Telepatch Cardiac Monitor |
| Astellas Pharma US INC | $12.94 | 2019 | |
| Preventice Services, LLC | $12.78 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Palermo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.